Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation by CEO Richard Paulson in two virtual investor conferences. The Wedbush PacGrow Healthcare Virtual Conference will take place on August 10, 2021, at 8:35 AM ET. The Canaccord Genuity 41st Annual Growth Conference is set for August 12, 2021, at 3:30 PM ET. Live webcasts will be available on the company's website, with replays archived for 30 days. Karyopharm focuses on pioneering cancer therapies and is known for its lead drug, XPOVIO®.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on August 2, 2021, that the Compensation Committee granted stock options to purchase 74,600 shares of common stock to 11 new employees. The options, with an exercise price of $8.33 per share, are part of the company's strategy to incentivize new hires. Each option vests over four years, with specific terms related to employment status and a potential 'change in control event.'
Karyopharm is focused on developing novel cancer therapies, including the approved drug XPOVIO (selinexor).
Karyopharm Therapeutics (Nasdaq: KPTI) will report its second quarter 2021 financial results on August 5, 2021. A conference call hosted by the management team is scheduled for 8:30 a.m. ET on the same day to discuss the results and provide company updates. Karyopharm specializes in developing novel cancer therapies, focusing on SINE compounds that inhibit the nuclear export protein XPO1, with its lead product XPOVIO already approved in the U.S. for various malignancies.
Karyopharm Therapeutics (NASDAQ: KPTI) announced the start of patient dosing in two new Phase 2 and 1/2 clinical studies for XPOVIO® (selinexor) in advanced melanoma and treatment-naïve myelofibrosis. The Phase 2 study will assess XPOVIO combined with Keytruda® in patients resistant to prior treatments. The Phase 1/2 study will evaluate XPOVIO with Jakafi® in treatment-naïve myelofibrosis patients. These studies follow promising preclinical and earlier clinical data, highlighting the ongoing need for innovative cancer therapies.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that it granted stock options to newly hired employees, including 125,000 shares to Ms. Sohanya Cheng, Senior VP, Sales and Commercial Operations, as an inducement for joining the company. The options have an exercise price of $10.32 per share, matching the closing price on June 30, 2021. Options vest over four years and may vest earlier upon termination without cause or a change in control event. This move aligns with Nasdaq Listing Rule 5635(c)(4) on compensatory stock option grants.
Karyopharm Therapeutics (NASDAQ: KPTI) announced an expanded royalty agreement with HealthCare Royalty Management for up to $100 million in financing to support the development of XPOVIO® (selinexor) and other programs. The initial $60 million has been received, with potential for two additional $20 million payments tied to milestones. XPOVIO is approved for multiple hematologic malignancies in the U.S. and has conditional marketing in Europe for multiple myeloma. Karyopharm expects the financing to sustain operations into mid-2023.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the selection of nine abstracts for virtual presentation at the European Hematology Association (EHA) 2021 Virtual Congress from June 9-17, 2021. The abstracts showcase clinical data on XPOVIO® (selinexor), including subgroup analyses from the Phase 3 BOSTON study and updated data from the Phase 1b/2 STOMP study. Notably, an oral presentation will focus on the combination treatment achieving a 78% overall response rate among multiple myeloma patients. This highlights Karyopharm's ongoing commitment to advancing cancer therapies.
Karyopharm Therapeutics (KPTI) reported positive Phase I/II results for eltanexor, a treatment for hypomethylating agent refractory myelodysplastic syndrome (MDS), during the ASCO Annual Meeting. Out of 15 evaluable patients, 47% achieved marrow complete response (mCR), and the total disease control rate was 80%. Notably, patients with mCR had a median overall survival (mOS) of 11.86 months, compared to 8.67 months for those without mCR. Eltanexor may offer a more tolerable option compared to first-generation inhibitors, with trials ongoing in Asia Pacific markets.
Karyopharm Therapeutics (Nasdaq: KPTI) announced significant management changes aimed at enhancing its commercial operations, including the appointment of Sohanya Cheng as Senior Vice President of Sales and Commercial Operations. Payman Darouian will oversee marketing for the company's lead product, XPOVIO (selinexor), while former executives John Demaree and Perry Monaco will leave to pursue other opportunities. Cheng, with 17 years in biopharmaceuticals, previously led marketing at Arrowhead Pharmaceuticals and has extensive oncology experience, contributing to the company's strategy for multiple myeloma and lymphoma.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the commercial availability of three new strength tablets for XPOVIO, following FDA approval on April 15, 2021. The new strengths of 40 mg, 50 mg, and 60 mg supplement the existing 20 mg tablet, enhancing patient compliance and treatment flexibility. XPOVIO is a first-in-class oral Selective Inhibitor of Nuclear Export (SINE) approved for multiple myeloma and diffuse large B-cell lymphoma. The new strengths do not alter the drug's efficacy or safety profile.
